Natural killer (NK) cell cytotoxicity is regulated by the action of a large number of distinct inhibitory and activating receptors that bind to the major histocompatibility complex (MHC) on the surface of target cells. Two major types of MHC class I-binding receptors are expressed on human NK cells: immunoglobulin (Ig) superfamily molecules, including killer cell Ig-like receptors (KIRs) and leukocyte Ig-like receptors (LIRs), and heterodimers of the C-type lectin-like molecules CD94 and natural killer group 2 (NKG2), including NKG2A/B, NKG2C, and NKG2E/H. 1,2) NKG2B and NKG2H are alternatively spliced variants of NKG2A and NKG2E, respectively. NKG2F has no C-type lectin-like domain and does not associate with CD94.
Human leukocyte antigen (HLA)-E serves as the ligand for CD94/NKG2A, CD94/NKG2C, and CD94/NKG2E. HLA-E is a non-classical MHC class Ib molecule loaded with nonamer leader peptides derived from the signal sequences of MHC class Ia, HLA-A, -B, -C, or -G proteins. [9] [10] [11] [12] Both the inhibitory CD94/NKG2A and activating CD94/NKG2C recognize the same nonamer peptide/HLA-E complex, although CD94/NKG2A has a higher binding affinity than CD94/ NKG2C. 13) These C-type lectin-like receptors lack most of the conserved Ca 2ϩ -binding region, and their glycan ligands have yet to be elucidated. 14) However, of the C-type lectin-like receptors on NK cells, several have been reported to recognize sulfated glycans: mouse Ly-49A binds to fucoidan [15] [16] [17] [18] and osteoclast inhibitory lectin (OCIL, lectin-like transcript 1: LLT1) binds to fucoidan, l-carrageenan, and dextran sulfate. 19) Preclinical and clinical studies suggest that heparin and low molecular weight heparins are effective in preventing tumor growth and metastasis. The molecular mechanisms of the anti-tumor effects of heparin are complicated and largely unclarified. Hypotheses include competition with the binding of growth factors to heparan sulfate proteoglycans, inhibition of heparanase, and inhibition of interaction with Land P-selectins on vascular endothelial cells and platelets. 20, 21) We demonstrated that K562 cells transfected with the fucosyltransferase 3 gene that highly express the sialyl Lewis X (sLeX) antigen, NeuAca2,3Galb1,4(Fuca1,3)GlcNAc-R, are more susceptible to in vitro lysis by KHYG cells. This susceptibility is suppressed by pretreatment of K562 cells with anti-sLeX and KHYG cells with anti-CD94 and anti-NKG2D. 22) In previous reports, 23, 24) we showed that recombinant glutathione-S-transferase (GST)-fused extracellular domains of NKG2D (rGST-NKG2D; AA 73-216) and CD94 (rGST-CD94; AA 68-179) directly bind to multimeric sLeXexpressing transferrin secreted by HepG2 cells (HepTF) and a2,3-NeuAc-remodeled human a 1 -acid glycoprotein (AGP), heparin/heparan sulfate, and sulfate-containing glycans, suggesting that glycans could modulate NK-cell-dependent cytotoxicity via activating or inhibitory NK cell receptors.
Here, we report that recombinant GST-fused extracellular domains (AA 94-231) of NKG2A (rGST-NKG2A) and NKG2C (rGST-NKG2C) bind to heparin and sulfate-containing glycans, and that this interaction is suppressed in the presence of soluble heparin, heparan sulfate, fucoidan, l-car-rageenan, and dextran sulfate. Moreover, rGST-NKG2A and rGST-NKG2C bind to sLeX or a2,3-NeuAc, but not to a2,6-NeuAc containing glycoproteins.
MATERIALS AND METHODS

Cells and Cell Culture
Human NK-derived KHYG cells from the Japanese Collection of Research Bioresources Cell Bank (JCRB) (Tokyo, Japan) were cultured in RPMI 1640 medium (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS, U.S.A.) and 0.6 mg/ml L-glutamate (Wako Pure Chemicals Co., Osaka, Japan) in a humidified atmosphere containing 5% CO 2 at 37°C. For culture of KHYG cells, recombinant interleukin-2 (Shionogi Pharmaceutical Co., Osaka, Japan) was added to the medium at a final concentration of 100 U/ml. Human hepatoma HepG2 cells (JCRB) were cultured in 10% FBS-containing Dulbecco's modified Eagle's medium (DMEM) (Nissui).
Preparation of rGST-NKG2A and rGST-NKG2C The genes corresponding to the extracellular domains of NKG2A and NKG2C (coding for AA 94-231 in each case) were amplified from KHYG-derived cDNA using the following primers: 5Ј-CACCTCTACATTAATACAGAGGCACAA-CAA-3Ј (forward) and 5Ј-CTAAAGCTTATGCTTACAAT-GAT-3Ј (reverse) for NKG2A, and 5Ј-CACCATTCCTTTC-CTGGAGCAGAA-3Ј (forward) and 5Ј-CTAAAGCTTAT-GCTTACAATGAT-3Ј (reverse) for NKG2C. Purified polymerase chain reaction (PCR) products were ligated into the pGEX4T-1 vector (GE Healthcare Bio-Science, Uppsala, Sweden) with Ligation High (Toyobo, Tokyo, Japan). Recombinant plasmids were transformed into Chaperone competent cells pTf16/BL21 (Takara, Otsu, Japan) and positive clones were confirmed by DNA sequencing.
After induction with 1 mM isopropyl-b-D-thiogalactopyranoside (Promega Co., Madison, WI, U.S.A.), the cells harvested by centrifugation at 3000 rpm for 10 min from 1000 ml culture medium were suspended in 3 ml phosphate buffered saline (PBS) and sonicated for 10 sϫ6 on ice. After centrifugation at 15000 rpm for 10 min, the lysate was passed through a 0.2-mm filter and then applied on a GSTrap TM FF column (GE Healthcare) according to the manufacturer's instructions. rGST-NKG2A and rGST-NKG2C were purified and dialyzed against 1 mM dithiothreitol (DTT)/PBS and were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with or without pretreatment in 1% 2-mercaptoethanol (2-ME) at 95°C for 3 min and stained with Coomassie brilliant blue. Protein concentrations were determined using the Advanced Protein Assay (Cytoskeleton, Denver, CO, U.S.A.) with BSA as a standard.
Assay for rGST-NKG2A and rGST-NKG2C Binding to Glycan-Coated Plates Binding of rGST-NKG2A and rGST-NKG2C to glycan-coated plates was determined according to previously reported methods. 23, 24) Briefly, sulfated glycans were conjugated with BSA in the presence of sodium cyanoborohydride and coated on the plates. HepTF purified from the culture supernatant of HepG2 cells, 25) commercially available human TF (NorTF) (Nacalai Tesque, Kyoto, Japan), and human AGP (Sigma-Aldrich, Chicago, IL, U.S.A.) were directly coated onto the plates. These glycoprotein-coated plates were further treated with 1 U/ml a2,3/6/8 neuraminidase (Seikagaku Co., Tokyo, Japan) in 100 mM MES (pH 6.0) for 2 d at 37°C. Binding of rGST-NKG2A and rGST-NKG2C on the plates was determined using peroxidase (POD)-conjugated anti-GST antibody (Rockland Immunochemicals Inc., Gilbertsville, PA, U.S.A.) and tetramethylbenzidine (TMB) (BioFX Laboratories, Owings Mills, MD, U.S.A.).
The Competition by Sulfate-Containing Glycans for Binding to Heparin-BSA Competition by soluble forms of glycans was determined by evaluating the binding of rGST-NKG2A and rGST-NKG2C (each 50 nM) to heparin-BSAcoated plates in the presence of 0, 1, 10, and 100 mg/ml of heparin (porcine intestinal mucosa; Wako); heparan sulfate (porcine intestinal mucosa; Funakoshi, Tokyo, Japan); dermatan sulfate (porcine intestinal mucosa; MP Biomedicals, Solon, OH, U.S.A.); keratan sulfate (bovine cornea; Seikagaku); chondroitin sulfate A (whale cartilage; Wako), B (pig skin; Wako), and C (shark cartilage; Wako); hyaluronic acid (pig skin; Seikagaku); mannan (yeast; Nacalai Tesque); fucoidan (marine algae; Sigma-Aldrich); l-carrageenan (Kappaphycus cottonii; Wako); dextran sulfate (Wako); and selectively desulfated heparin. Selectively desulfated heparin, including 2-O-, 6-O-, and N-desulfated heparin, was prepared according to the previous report. 24) RESULTS rGST-NKG2A and rGST-NKG2C Bind to Heparin-BSA To evaluate the molecular forms of rGST-NKG2A and rGST-NKG2C, these proteins were purified on a glutathione column, treated with or without 1% 2-ME, and subjected to 10% SDS-PAGE. These recombinant proteins formed bands under non-reducing conditions at around 43 kDa, similar to reduced proteins, indicating that monomeric forms were mainly obtained (Fig. 1) .
To ascertain whether NKG2A and NKG2C bind to sulfatecontaining glycans, we determined the binding of rGST-NKG2A and rGST-NKG2C to heparin-BSA-coated plates using POD-conjugated anti-GST (Fig. 2) . Both rGST-NKG2A and rGST-NKG2C bound to heparin-BSA in a dosedependent fashion (Figs. 2A, B) (Figs. 2C, D) , respectively. These results indicated that NKG2A and NKG2C bind to heparin with similarly high affinity.
Competition of rGST-NKG2A and rGST-NKG2C for Binding to Heparin-BSA To investigate whether NKG2A and NKG2C bind to other sulfate-containing glycans, the binding of rGST-NKG2A and rGST-NKG2C (each 50 nM) to heparin-BSA-coated plates was assayed in the presence of 0, 1, 10, and 100 mg/ml of various soluble glycans (Fig. 3) . The binding of rGST-NKG2A (Fig. 3A) and rGST-NKG2C (Fig.  3B ) to heparin-BSA-coated plates was significantly suppressed by sulfated glycans in the order of fucoidan, l-carrageenan, and dextran sulfate heparin and heparan sulfate. Furthermore, the binding of rGST-NKG2A and rGST-NKG2C to HepTF-coated plates was significantly suppressed by heparin (data not shown). Even at the highest concentration tested (100 mg/ml), chondroitin sulfate A, B, and C, dermatan sulfate, keratan sulfate, hyaluronic acid, and mannan did not affect the binding of rGST-NKG2A and rGST-NKG2C to heparin-BSA. K d values of rGST-NKG2A and rGST-NKG2C were 212 nM (R 2 ϭ0.9755) and 164 nM (R 2 ϭ 0.9846) for heparan sulfate-BSA and 1.35 nM (R 2 ϭ0.9990) and 0.27 nM (R 2 ϭ0.9980) for fucoidan-BSA, respectively. Next, we investigated the binding of NKG2A and NKG2C to selectively desulfated heparin (Fig. 4) . rGST-NKG2A and rGST-NKG2C were incubated in the presence of soluble 2-O-, 6-O-, and N-desulfated heparin on heparin-BSA-coated plates to determine whether sulfate residues in heparin are essential for their binding. Binding of rGST-NKG2A and rGST-NKG2C (each 50 nM) to heparin-BSA was suppressed by soluble 6-O-and N-desulfated heparin, but not by 2-Odesulfated heparin at the highest concentration (100 mg/ml) (Figs. 4A, B) . These results indicated that 2-O-sulfate residues in heparin are essential for the binding of rGST-NKG2A and rGST-NKG2C.
Binding of rGST-NKG2A and rGST-NKG2C to NeuAc-Containing Glycoproteins To clarify whether NKG2A and NKG2C can bind to NeuAc-containing glycoproteins, the binding of rGST-NKG2A and rGST-NKG2C to HepTF, NorTF, AGP, and desialylated HepTF was investigated (Fig. 5) . Hep-TF expresses multivalent sLeX in di-to tetra-antennary N-glycans, 25) while NorTF has a2,6-NeuAc in di-antennary N-glycans, 26) and human AGP has a2,6-NeuAc in di-to tetra-antennary N-glycans. 27, 28) rGST-NKG2A and rGST-NKG2C (each 200 nM) bound directly to HepTF-coated plates but less to NorTF and AGP, and desialylated HepTF restrained the binding (Figs. 5A, B) . K d values of rGST-NKG2A and rGST-NKG2C for HepTF were determined to be 80 (R 2 ϭ0.9903) and 114 nM (R 2 ϭ0.9514), respectively (Figs. 5C, D) . These results revealed that NKG2A and NKG2C bind to multimeric a2,3-NeuAc-containing gly- 482 Vol. 34, No. 4
Fig. 1. SDS-PAGE for rGST-NKG2A and rGST-NKG2C
Recombinant proteins purified on a glutathione column were treated under reducing (R) and non-reducing (NR) conditions and separated by SDS-10% PAGE. Fig. 2 . Binding of rGST-NKG2A and rGST-NKG2C to Heparin-BSA (A) rGST-NKG2A and (B) rGST-NKG2C (each 0 to 250 nM) were incubated on heparin-BSA-coated plates for 2 h at 37°C, followed by incubation with 1 mg/ml POD-conjugated anti-GST for 1 h at room temperature. POD activity was determined using TMB-1 reagent. Non-specific GST binding was subtracted from the data. coproteins.
DISCUSSION
In the present report, we clarified that rGST-NKG2A and rGST-NKG2C bind to heparin-BSA with similarly high affinities. The heparin binding of rGST-NKG2A and rGST-NKG2C was significantly suppressed by sulfated glycans in the order of fucoidan, l-carrageenan, and dextran sulfate heparin and heparan sulfate, but not by chondroitin sulfate A, B, and C, dermatan sulfate, keratan sulfate, hyaluronic acid, or mannan. Moreover, a competition binding assay revealed that 2-O-sulfate residues in heparin are essential for the binding of rGST-NKG2A and rGST-NKG2C to heparin.
K d values of rGST-NKG2A and rGST-NKG2C were 212 and 164 nM for heparan sulfate-BSA, 80 and 114 nM for HepTF, 20 and 40 nM for heparin-BSA, and 1.35 and 0.27 nM for fucoidan-BSA, respectively. The binding affinity of heparin-BSA is higher than that of HepTF. K d values of rGST-NKG2A and rGST-NKG2C for heparin-BSA were one or two orders of magnitude smaller than those of rGST-NKG2D (1.11 mM) and rGST-CD94 (1.45 mM), 29) and compatible to those of natural cytotoxicity receptors (NCRs). 30, 31) The extracellular domain sequences of NKG2A and NKG2C are 92% identical; however, the binding affinity of CD94/NKG2A for HLA-E is six-to eight-fold higher than that of CD94/NKG2C. 13, 32, 33) Alterations in the heterodimer interface between NKG2A and NKG2C may impact binding affinity. 32, [34] [35] [36] HLA-E mutation analysis indicates that CD94/NKG2A and CD94/NKG2C bind to the top of the HLA-E a1/a2 domain. 37) The interaction of an acidic region on CD94 with a basic region on the a1 helix of HLA-E, and a basic patch on NKG2A with an acidic region on the a2 helix of HLA-E, are also important for the binding of CD94/NKG2A to HLA-E. 12, 32, 36) Several amino acid residues in NKG2A are essential for recognition of HLA-E. 12, [34] [35] [36] In a preliminary study, we prepared rGST-NKG2A mutants R137A, P171A, S172A, K199A, Q212A, R215A, and K217A, which are residues responsible for NKG2A recognition of HLA-E, and determined the binding of these mutants to heparin-BSA. Binding of rGST-NKG2A mutants was restrained by substitutions P171A, K199A, and R215A, suggesting that the heparin binding sites of NKG2A may partially overlap with the HLA-E binding sites (data not shown). Basic amino acids in NKp44 30) and in NKp46 38) are involved in their respective binding to heparin/heparan sulfate. On the other hand, heparin binding is suppressed by NKG2D mutants Y199A and Y152A, and CD94 mutants F114A and N160A. 24) These results suggest that NKG2A and NKG2C recognize heparin mainly by ionic interactions similar to NCRs, while NKG2D and CD94 bind to heparin by hydrophobic interactions. Further study is needed to clarify whether the interactions of CD94/NKG2A and CD94/NKG2C with sulfated glycans and a2,3-NeuAc-containing glycoproteins can modulate cellular signaling and are relevant to natural immunity in cancer progression and metastasis. 
